Marshall Wace
NERV icon

Marshall Wace’s Minerva Neurosciences NERV Stock Holding History

Marshall Wace’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-218,759
Closed -$1.32M – 3543
2026
Q1 		$1.32M Buy
+218,759
New +$1.25M ﹤0.01% 1999
2017
Q1 		– Sell
-55,353
Closed -$5.2M – 597
2016
Q4 		$5.2M Buy
55,353
+1,511
+3% +$154K 0.03% 460
2016
Q3 		$6.08M Buy
53,842
+21,154
+65% +$2.05M 0.04% 372
2016
Q2 		$2.67M Buy
+32,688
New +$2.08M 0.02% 522

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's NERV Position: Q2 2026 in Review

Marshall Wace sold out of Minerva Neurosciences (NERV) in Q2 2026, closing a stake of 218,759 shares — an estimated $1.32M sold.

Marshall Wace first reported a position in NERV in Q2 2016 and held it in 4 quarters. The position peaked at $6.08M in Q3 2016. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Marshall Wace reported no remaining Minerva Neurosciences position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 218,759 Minerva Neurosciences shares in Q2 2026, an estimated $1.32M.
  • Marshall Wace first reported a position in Minerva Neurosciences in Q2 2016 and held it in 4 quarters.
  • Marshall Wace's Minerva Neurosciences position peaked at $6.08M in Q3 2016.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.